Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will ...
View Compugen Ltd. CGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.
COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate 22% (2/9) and disease control rate 44%) with a ...
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer ...
Compugen Systems Inc. is proud to announce the relocation of its corporate headquarters to Syracuse, NY, the launch of a refreshed brand identity anchored by the new positioning statement "Service is ...
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...
Ambitious Israel-based biotech Compugen's (NASDAQ: CGEN) stock had one of the best days in its history Thursday. The shares rose 14% after the company revealed that a deep-pocketed strategic investor ...
HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI ...
Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with AstraZeneca (AZN) to monetize a portion of future royalties linked to its ...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...
Compugen focuses on finding cancer-fighting therapies. The company is a clinical-stage biotech with little revenue. Compugen said it plans to present clinical data at an upcoming conference. The other ...
The company is deepening its partnership with Bristol Myers Squibb. The two companies are already collaborators in the laboratory. In two studies, Compugen's COM701 is being tested in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results